Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.46 |
| ▸ | MC4R | P32245 | 6/20 | 0.43 |
| ▸ | MC3R | P41968 | 2/20 | 0.43 |
| ▸ | MC5R | P33032 | 1/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13474730 | 0.85 | PRCP (0.44) | OPRL1MC4RPRCP | |
| SCHEMBL29904553 | 0.85 | PRCP (0.44) | OPRL1MC4RPRCP | |
| SCHEMBL1824551 | 0.81 | OPRL1 (0.58) | OPRL1PROKR1HTR2CHTR2B | |
| SCHEMBL1822952 | 0.78 | PROKR1 (0.46) | OPRL1MC4RMC3RMC5RPROKR1 | |
| SCHEMBL13473961 | 0.77 | MC4R (0.53) | MC4RMC3RMC5RPRCP | |
| SCHEMBL4969208 | 0.77 | OPRL1 (0.64) | OPRL1PROKR1HTR2AHTR2CHTR2B | |
| SCHEMBL24775527 | 0.77 | HSD11B1 (0.47) | — | |
| SCHEMBL18741868 | 0.76 | APLNR (0.37) | OPRL1MC4RMC3RMC5RPROKR1 | |
| SCHEMBL29736498 | 0.75 | DRD2 (0.50) | PROKR1 | |
| SCHEMBL27394358 | 0.75 | DRD2 (0.50) | PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301286-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301286-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | OPRL1 61/4885MC4R 2/4885MC3R 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.